Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07154615 · ClinicalTrials.gov registry record
Assessing Immune Dysfunction in Sepsis
A clinical trial of Sepsis, sponsored by University of Minnesota.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT07154615: Recruiting study of Sepsis, sponsored by University of Minnesota.
NCT07154615 is a study of Sepsis that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 150 participants, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07154615, a study of Sepsis, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the \~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.
Primary Outcome
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes
Conditions Studied
Interventions
- OTHER Observational Only
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2028-11-01 |
What NCT07154615 shows while recruiting
NCT07154615 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 6,563-participant average among 90 other Sepsis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Sepsis appearing as the primary indexed condition, and to 1 intervention - of which Observational Only is the first listed.
NCT07154615 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT07154615 about?
NCT07154615 is a clinical study titled "Assessing Immune Dysfunction in Sepsis". Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the \~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective...
What is the current status of trial NCT07154615?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2026-03-01. Estimated completion is 2028-11-01.
What conditions does trial NCT07154615 study?
This clinical trial studies the following conditions: Sepsis.
What interventions are being tested in trial NCT07154615?
The interventions under investigation include: Observational Only (OTHER).
Who is sponsoring clinical trial NCT07154615?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07154615 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sepsis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07154615's enrollment target sits among peer trials
150 48th of 90 higher than 41 of 90 other Sepsis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sepsis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The APS Phenotyping Study
RECRUITING
-
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
RECRUITING · Phase 2
-
Early Versus Late Adjunctive Vasopressin in Septic Shock
RECRUITING · Phase 4
-
Renin Angiotensin Aldosterone System In Septic Kids
RECRUITING
-
The RightCall: Implementing a Sepsis Diagnostic Toolkit to Improve Pediatric Diagnosis in ED Transfer Calls
RECRUITING · NA
-
External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI